Loading...
•
Dec 31, 2019
Dynavax Q4 2019 Earnings Report
Dynavax reported financial results for the fourth quarter and full year 2019.
Key Takeaways
Dynavax's Q4 2019 earnings show a net product revenue of $10.6 million, a significant increase from $3.9 million in Q4 2018. The company's market share in targeted accounts also rose to 21% from 18% in the previous quarter. The net loss allocable to common stockholders was $36.8 million, or $0.44 per share.
HEPLISAV-B net product revenue for Q4 2019 was $10.6 million, up from $3.9 million in Q4 2018.
Market share in accounts targeted by the field sales team increased to 21% in Q4 2019 from 18% in Q3 2019.
Net loss allocable to common stockholders for Q4 2019 was $36.8 million, or $0.44 per basic and diluted share.
Cash, cash equivalents and marketable securities totaled $151.1 million at December 31, 2019.
Revenue by Segment
Forward Guidance
Dynavax anticipates HEPLISAV-B® net product revenue to increase to $55-$62 million for the full year 2020. They plan to release interim data from an ongoing study of HEPLISAV-B in patients on hemodialysis in Q1 2020 and final immunogenicity data in the second half of 2020. They also aim to complete safety follow-up for HEPLISAV-B post-marketing studies in Q4 2020.
Positive Outlook
- HEPLISAV-B® net product revenue expected to increase to $55-$62 million for the full year 2020
- Release interim data from ongoing study of HEPLISAV-B in patients on hemodialysis in Q1 2020 and final immunogenicity data in the second half of 2020
- Complete Phase 1-enabling animal studies and toxicology for improved pertussis vaccine with CpG 1018
- Enter multiple strategic relationships focused on initial research in a variety of vaccine candidates to establish CpG 1018 as a leading adjuvant
- Complete safety follow-up for HEPLISAV-B post-marketing studies in Q4 2020
Challenges Ahead
- The vaccine market and/or the adult hepatitis B market may not grow as expected
- HEPLISAV-B may not provide the anticipated benefits and may not become the standard of care adult hepatitis B vaccine in the U.S.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...